Frederick Locke, MD

Articles

Dr. Locke on Bridging Chemotherapy in Patients With Non-Hodgkin Lymphoma

September 13th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of bridging chemotherapy in patients receiving chimeric antigen receptor (CAR) T-cell therapy.

Dr. Locke on CAR T-Cell Therapy in NHL

September 10th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with non–Hodgkin lymphoma (NHL).

Dr. Locke Discusses Unanswered Questions With CAR T-Cell Therapy

September 5th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses unanswered questions with chimeric antigen receptor T-cell therapy.

Dr. Locke Discusses the Impact of the ZUMA-1 Trial in NHL

February 14th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses the impact of the ZUMA-1 trial for patients with non-Hodgkin Lymphoma (NHL).

Dr. Locke Discusses Long-Term Follow-Up of ZUMA-1 Trial for NHL

February 7th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses long-term follow-up results of the ZUMA-1 trial for patients with non-Hodgkin lymphoma (NHL).

Dr. Locke on the ZUMA-6 Trial of Axi-Cel With Atezolizumab for DLBCL

January 26th 2018

Frederick Locke, MD, Moffitt Cancer Center, discusses the results of the ZUMA-6 trial investigating axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab (Tecentriq) for the treatment of patients with refractory diffuse large B-cell lymphoma (DLBCL).

Dr. Locke on the ZUMA-1 Trial of KTE-C19 for Lymphoma

February 26th 2017

Fred Locke, MD, Moffitt Cancer Center discusses the interim results of the ZUMA-I trial of Kte-C19, a CAR T-cell therapy.

Dr. Frederick Locke on KTE-C19 for Refractory NHL

January 13th 2016

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses KTE-C19 for the treatment of refractory aggressive non-Hodgkin lymphoma (NHL).

x